Literature DB >> 19422893

Differentially conserved staphylococcal SH3b_5 cell wall binding domains confer increased staphylolytic and streptolytic activity to a streptococcal prophage endolysin domain.

Stephen C Becker1, Juli Foster-Frey, Angeline J Stodola, Daniel Anacker, David M Donovan.   

Abstract

Staphylococcal peptidoglycan hydrolases are a potential new source of antimicrobials. A large subset harbors C-terminal SH3b_5 cell wall binding domains. These C-terminal domains have been shown to be necessary for accurate cell wall recognition and subsequent staphylolytic activity for some endolysins. Over fifty proteins of staphylococcal or phage origin containing SH3b domains were aligned, yielding five highly repetitive groups of proteins. Representative C-termini from these five groups, and six staphylococcal proteins for which no homologues have been identified, were aligned, revealing two distinct SH3b_5 subgroups with overlapping but differentially conserved residues. A premise behind this research is that there may be unique cell wall binding properties conferred by these staphylococcal domains that could be exploited to specifically enhance anti-staphylococcal efficacy in heterologous protein fusion constructs. To identify functional differences between the two subgroups, the native Cpl-7 cell wall binding domains of the streptococcal LambdaSa2 endolysin were replaced by staphylococcal SH3b domains from both subgroups. SH3b domains from either lysostaphin (bacteriocin) or LysK (phage endolysin) resulted in a approximately 5x increase in staphylolytic activity conferred on the streptococcal endopeptidase domain, and surprisingly these same fusions maintained significant streptolytic activity suggesting that the staphylococcal SH3b domains are not always staphylococcal-specific. A comparison of the differences in lytic activity conferred on the LambdaSa2 endopeptidase domain by either LysK or lysostaphin SH3b domain differed by no more than a factor of two. Through the collection of peptidoglycan hydrolase sequences, three new putative intron-containing phage endolysin genes were identified in public data sets for the phages G1, X2 and 85.

Mesh:

Substances:

Year:  2009        PMID: 19422893     DOI: 10.1016/j.gene.2009.04.023

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  49 in total

1.  Staphylococcal phage 2638A endolysin is lytic for Staphylococcus aureus and harbors an inter-lytic-domain secondary translational start site.

Authors:  Igor Abaev; Juli Foster-Frey; Olga Korobova; Nina Shishkova; Natalia Kiseleva; Pavel Kopylov; Sergey Pryamchuk; Mathias Schmelcher; Stephen C Becker; David M Donovan
Journal:  Appl Microbiol Biotechnol       Date:  2012-07-10       Impact factor: 4.813

2.  Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands.

Authors:  Mathias Schmelcher; Anne M Powell; Stephen C Becker; Mary J Camp; David M Donovan
Journal:  Appl Environ Microbiol       Date:  2012-01-27       Impact factor: 4.792

3.  Role of net charge on catalytic domain and influence of cell wall binding domain on bactericidal activity, specificity, and host range of phage lysins.

Authors:  Lieh Yoon Low; Chen Yang; Marta Perego; Andrei Osterman; Robert Liddington
Journal:  J Biol Chem       Date:  2011-08-04       Impact factor: 5.157

Review 4.  Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery Strategies.

Authors:  Hamed Haddad Kashani; Mathias Schmelcher; Hamed Sabzalipoor; Elahe Seyed Hosseini; Rezvan Moniri
Journal:  Clin Microbiol Rev       Date:  2017-11-29       Impact factor: 26.132

5.  Evolutionarily distinct bacteriophage endolysins featuring conserved peptidoglycan cleavage sites protect mice from MRSA infection.

Authors:  Mathias Schmelcher; Yang Shen; Daniel C Nelson; Marcel R Eugster; Fritz Eichenseher; Daniela C Hanke; Martin J Loessner; Shengli Dong; David G Pritchard; Jean C Lee; Stephen C Becker; Juli Foster-Frey; David M Donovan
Journal:  J Antimicrob Chemother       Date:  2015-01-27       Impact factor: 5.790

6.  Molecular aspects and comparative genomics of bacteriophage endolysins.

Authors:  Hugo Oliveira; Luís D R Melo; Sílvio B Santos; Franklin L Nóbrega; Eugénio C Ferreira; Nuno Cerca; Joana Azeredo; Leon D Kluskens
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

Review 7.  Genetically Engineered Phages: a Review of Advances over the Last Decade.

Authors:  Diana P Pires; Sara Cleto; Sanna Sillankorva; Joana Azeredo; Timothy K Lu
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-01       Impact factor: 11.056

8.  Staphylococcus haemolyticus prophage ΦSH2 endolysin relies on cysteine, histidine-dependent amidohydrolases/peptidases activity for lysis 'from without'.

Authors:  Mathias Schmelcher; Olga Korobova; Nina Schischkova; Natalia Kiseleva; Paul Kopylov; Sergey Pryamchuk; David M Donovan; Igor Abaev
Journal:  J Biotechnol       Date:  2012-09-28       Impact factor: 3.307

Review 9.  Bacteriophage endolysins as novel antimicrobials.

Authors:  Mathias Schmelcher; David M Donovan; Martin J Loessner
Journal:  Future Microbiol       Date:  2012-10       Impact factor: 3.165

10.  Prophage lysin Ply30 protects mice from Streptococcus suis and Streptococcus equi subsp. zooepidemicus infections.

Authors:  Fang Tang; Dezhi Li; Haojin Wang; Zhe Ma; Chengping Lu; Jianjun Dai
Journal:  Appl Environ Microbiol       Date:  2015-08-07       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.